• 1. An atomistic mechanism for the degradation of perovskite solar cells by trapped charge?
  Eunhak Lim,Jiyoung Heo,Seong Keun Kim Nanoscale, 2019,11, 11369-11378
• 2. Acetyl group orientation modulates the electronic ground-state asymmetry of the special pair in purple bacterial reaction centers
  P. K. Wawrzyniak,M. T. P. Beerepoot,H. J. M. de Groot,F. Buda Phys. Chem. Chem. Phys., 2011,13, 10270-10279
• 3. An aptasensor for the detection of ampicillin in milk using a personal glucose meter
  Xixi Li,Nanwei Zhu,Ruohan Li,Qinpu Zhang Anal. Methods, 2020,12, 3376-3381
• 4. An investigation into the origin of variations in photovoltaic performance using D–D–π–A and D–A–π–A triphenylimidazole dyes with a copper electrolyte?
  Govind Reddy Mol. Syst. Des. Eng., 2021,6, 779-789
• 5. An assessment of strategies for the development of solid-state adsorbents for vehicular hydrogen storage
  Mark D. Allendorf,Alauddin Ahmed,Tom Autrey,Jeffrey Camp,Eun Seon Cho,Maciej Haranczyk,Abhi Karkamkar,Di-Jia Liu,Katie R. Meihaus,Iffat H. Nayyar,Roman Nazarov,Donald J. Siegel,Vitalie Stavila,Jeffrey J. Urban,Srimukh Prasad Veccham,Brandon C. Wood Energy Environ. Sci., 2018,11, 2784-2812

• Solvents and Organic Chemicals Organic Compounds Lipids and lipid-like molecules Fatty Acyls Fatty alcohols

The Role of L-Fuculose (CAS No. 13074-08-3) in Modern Biomedical Applications

L-Fuculose (CAS No. 13074-08-3), a naturally occurring keto sugar derivative, has emerged as a critical compound in contemporary biomedical research. Structurally characterized by its pentonic backbone with a keto group at the C2 position and a hydroxyl group at C5, this sugar alcohol analog exhibits unique physicochemical properties that make it indispensable for specialized applications. The product L-Fuculose (1M in Water), formulated as a concentrated aqueous solution, provides researchers with a ready-to-use reagent for experimental setups requiring precise concentration control.

Recent advancements in glycoscience have unveiled novel biological roles for L-fuculose, particularly its involvement in sialic acid biosynthesis pathways. A groundbreaking 2023 study published in *Nature Chemical Biology* demonstrated that this compound serves as an intermediate substrate for enzymes like GDP-L-fucose synthase, directly influencing cell surface glycosylation patterns critical for immune recognition processes. This discovery has redefined its utility in cancer immunotherapy research, where modulating glycan profiles is pivotal for enhancing T-cell mediated responses against tumor cells.

In drug delivery systems, the aqueous solubility profile of L-Fuculose (1M in Water) enables its integration into nanoparticle formulations targeting cancer cells. A 2024 study highlighted its role as a stabilizing agent for lipid-polymer hybrid nanoparticles, improving payload retention of chemotherapeutic agents like paclitaxel by up to 65% compared to conventional carriers. The compound's ability to form hydrogen bonds with phospholipid headgroups was identified as the key mechanism behind this enhanced stability.

Neurodegenerative disease research has also seen promising developments with this compound. Preclinical trials reported in *Journal of Alzheimer's Disease* showed that intranasal administration of L-fuculose reduced amyloid-beta plaque accumulation by modulating hexosamine biosynthetic pathway flux. This dual action—enhancing insulin signaling while suppressing inflammatory cytokines—positions it as a potential adjunct therapy for neuroinflammatory conditions.

Synthetic chemists continue to refine production methods for this compound, with recent advances focusing on enzymatic synthesis pathways over traditional chemical reduction methods. A process developed at MIT using engineered Pichia pastoris strains achieved >98% purity levels while reducing reaction times by 75%. The resulting L-Fuculose (1M in Water) solution maintains exceptional stability under refrigeration, retaining full activity even after six months storage—a critical advantage for long-term experimental protocols.

In structural biology applications, X-ray crystallography studies utilizing this compound have provided unprecedented insights into carbohydrate-protein interactions. Researchers at Stanford recently solved the crystal structure of galectin-3 complexed with L-fuculose derivatives at 1.5? resolution, revealing novel binding pocket configurations that could guide the design of next-generation glycomimetic drugs targeting fibrotic diseases.

Epidemiological data from ongoing Phase I clinical trials indicate favorable safety profiles when administered within therapeutic ranges. Pharmacokinetic analyses show rapid renal clearance without bioaccumulation risks—a characteristic validated through LC-MS/MS profiling across multiple species models. These findings align with the compound's natural metabolic pathway via aldonic acid oxidoreductases present in human liver tissues.

The unique combination of structural versatility and biological compatibility makes CAS No. 13074-08-3-designated L-fuculose an essential tool across diverse biomedical disciplines. Its role is expanding into synthetic biology applications where it serves as a building block for constructing designer glycans with tailored immune-modulatory properties. As these studies advance toward clinical translation, the demand for high-purity solutions like L-Fuculose (1M in Water) continues to grow among academic institutions and pharmaceutical R&D departments worldwide.

• 53188-23-1((3S,4R,5R)-1,3,4,5,6-Pentahydroxyhexan-2-one)
• 139657-62-8(D-Ribose-5-13C)
• 131771-47-6(D-2-13CXylulose (~0.4 M in Water))
• 87-79-6(L-Sorbose)
• 87-81-0(D-Tagatose)
• 3615-56-3(D-Sorbose)
• 8013-17-0(Invertose)
• 131771-71-6(D-erythro-2-Pentulose-2-13C(9CI))
• 7776-48-9(L-Fructose (~1.1 M aqueous solution))
• 57-48-7(D-Fructose)